In this study, the investigators will prospectively recruit 100,000 individuals, including gastric cancer patients who have not undergone any anti-tumor treatment and non-gastric cancer participants. The investigators will construct a diagnostic model for malignant tumors based on the combination of tongue imaging, tongue coating, saliva, gastric juice, and fecal multi-omics data (including metagenomics, proteomics, metabolomics, etc.). Additionally, the study will explore the relationship between oral, gastric, and intestinal microbiota and the development of malignant tumors.
18≤age≤90
Histologically or cytologically confirmed gastric cancer
No prior chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor treatment for gastric cancer
Subject volunteers to join the study, Signs informed consent, has good compliance and can cooperate with follow-up
Two or more kinds of malignant tumors at the same time
Gastric cancer that has been treated by chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor therapy
The use of glucocorticoids and antibiotics in the past three months
History of long-term medication
Histologically or cytologically confirmed gastric cancer, and no prior chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor treatment for malignant tumor. Gastric cancer patients and healthy participants should not have the following conditions: the use of glucocorticoids and antibiotics in the past three months, a history of long-term medication, as well as oral diseases such as tooth and gum diseases.
Case-control
Prospective
Tongue imaging, tougue coating, saliva, gastric juice, and feces
Diagnostic testTongue images, coating, saliva, gastric juice, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
The differences in tongue images, tongue coating, saliva, gastric juice, and fecal samples between patients with gastric cancer and healthy individuals will be systematically analyzed.
The differences of the clinical information between patients with gastric cancer and healthy participants.
These data of gastric cancer group included age, sex, height, weight, family history, smoking, drinking, TNM staging, tumor location, tumor size, pathological type, grade of differentiation, expression of Her2, nerve invasion, vascular tumor thrombus, lauren type and and blood tumour markers, and these data of healthy participants group included age, sex, height, weight, smoking, drinking and blood tumour markers.
Overall Survival (OS)
Disease Free Survival (DFS)
Click on the lead sponsor to view all of their trials.
Zhejiang Cancer Hospital
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Collaborator
The First Affiliated Hospital of Zhejiang Chinese Medical University
Collaborator
Wenzhou Medical University
Collaborator
Fujian Cancer Hospital
Collaborator
RenJi Hospital
Collaborator
Zhejiang Provincial Tongde Hospital
Collaborator
Kecheng District People's Hospital
Collaborator
Yueyang Central Hospital
Collaborator
Shandong Cancer Hospital and Institute
Collaborator
Shanxi Province Cancer Hospital
Collaborator
Liaoning Cancer Hospital & Institute
Collaborator
Harbin Cancer Hospital
Collaborator
Yuhang District People's Hospital
Collaborator
Hainan Cancer Hospital
Collaborator
Zigong Fourth People's Hospital
Collaborator
Henan University of Science and Technology
Collaborator
Shangyu People's Hospital of Shaoxing City
Collaborator
Red Cross Hospital, Hangzhou, China
Collaborator
The Affiliated Hospital of Hangzhou Normal University
Collaborator
Xiaoshan District First People's Hospital
Collaborator
Xianju People's Hospital
Collaborator
Lin'an District First People's Hospital
Collaborator
First Affiliated Hospital of Wenzhou Medical University
Collaborator
Wenzhou Central Hospital
Collaborator
The Third Affiliated Hospital of Wenzhou Medical University
Collaborator
Leqing City People's Hospital
Collaborator
The Affiliated Hospital of Medical School of Ningbo University
Collaborator
Cixi City People's Hospital
Collaborator
Mingzhou Hospital, Zhejiang University
Collaborator
Fourth Hospital of Ningbo City
Collaborator
Fenghua District People's Hospital
Collaborator
Fenghua Traditional Chinese Medicine Hospital, Ningbo City
Collaborator
Xikou Hospital, Fenghua District, Ningbo City
Collaborator
Chengdu University of Traditional Chinese Medicine
Collaborator
Guang'an Hospital, Affiliated to Chengdu University of Traditional Chinese Medicine
Collaborator
Jiangsu Cancer Institute & Hospital
Collaborator
Jiangsu Provincial People's Hospital
Collaborator
The First People's Hospital of Changzhou
Collaborator
The First Affiliated Hospital of Soochow University
Collaborator
Jiangsu Province Hospital of Traditional Chinese Medicine
Collaborator
Zidong Campus of Jiangsu Provincial Hospital of TCM
Collaborator
Wuxi Traditional Chinese Medicine Hospital
Collaborator
First Affiliated Hospital of Harbin Medical University
Collaborator
The First Affiliated Hospital of Anhui Medical University
Collaborator
Peking University Cancer Hospital & Institute
Collaborator
Xijing Hospital
Collaborator
Guangdong Provincial Hospital of Traditional Chinese Medicine
Collaborator
Xiangya Hospital of Central South University
Collaborator
Yunnan Cancer Hospital
Collaborator
Chongqing University Cancer Hospital
Collaborator
Gansu Cancer Hospital
Collaborator
Fudan University
Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborator
First Affiliated Hospital of Guangxi Medical University
Collaborator
Tianjin Medical University Cancer Institute and Hospital
Collaborator
Huzhou Central Hospital
Collaborator
Zhoushan Hospital, Zhejiang
Collaborator
